Peer-influenced content. Sources you trust. No registration required. This is HCN.

Practical NeurologyAducanumab Appropriate Use for Alzheimer Disease Treatment Recommendations Updated

The update, which was presented during a panel discussion at the Alzheimer Association International Conference 2022 (AAIC2022) in San Diego, CA, is based on evidence from real-world use of aducanumab and is intended to improve risk mitigation, safety monitoring, patient selection, and shared decision-making.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form